Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401973 · ClinicalTrials.gov registry record · Phase 3
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 199
- Enrollment target
NCT00401973 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 199 participants.
The verdict
NCT00401973, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 199 participants
- Enrollment target
Study Summary
The goal of this study is to answer the following questions: * Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine * Whether taking amantadine, metformin or zonisamide can help patients decrease or eliminate some of the changes in body that occur with weight gain * How weight gain associated with olanzapine can affect people * Whether treatment with amantadine, metformin or zonisamide can help eliminate weight gain associated with olanzapine and not interfere with the positive effects of olanzapine on functioning of people with schizophrenia and other diseases
Interventions
- DRUG metformin
- DRUG olanzapine
- DRUG zonisamide
- DRUG amantadine
- BEHAVIORAL Wellness education
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401973
The ClinicalTrials.gov registry entry for NCT00401973 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which metformin is the first listed.
NCT00401973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401973 about?
NCT00401973 is a clinical study titled "Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine". The goal of this study is to answer the following questions: * Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine * Whether taking amantadine, metformin or zonisamide can help patients decrease or eliminate some of th...
What is the current status of trial NCT00401973?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 199 participants. The study started on 2006-11. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00401973?
The interventions under investigation include: metformin (DRUG), olanzapine (DRUG), zonisamide (DRUG), amantadine (DRUG), Wellness education (BEHAVIORAL).
Who is sponsoring clinical trial NCT00401973?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.